You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Introduction

Onychomycosis is a common fungal infection of the nail that is most frequently caused by a dermatophyte. Onychomycosis is most prevalent in the toenails of adults and is more commonly found in patients with certain comorbid diseases such as diabetes, tinea pedis, and psoriasis. Management of onychomycosis includes a multispecialty team of healthcare providers. Early treatment of this infection, and new topical therapies are providing expanded options so clinicians can individualize treatment for this difficult to manage condition.

Activities

Steering Committee

Steering Committee Chair
  • Boni E. Elewski, MDBoni E. Elewski, MD
    Professor, University of
    Alabama, Birmingham
Steering Committee Members
  • Aditya K. Gupta, MD, PhD, FRCPC, FAAD, MBAAditya K. Gupta, MD, PhD, FRCPC, FAAD, MBA
    Professor, University of Toronto, Toronto, Ontario
  • Jeffrey M. Robbins, DPMJeffrey M. Robbins, DPM
    Professor of Podiatric Medicine; Director, Podiatry Services VACO; Kent State University College of Podiatric Medicine, Independence, Ohio
  • Dyanne P. Westerberg, DODyanne P. Westerberg, DO
    Associate Professor, Cooper Medical School of Rowan University, Camden, New Jersey
  • Tracey C. Vlahovic, DPM, FFPM RCPS (Glasg)Tracey C. Vlahovic, DPM, FFPM RCPS (Glasg)
    Associate Professor, Temple University School of Podiatric Medicine, Philadelphia, Pennsylvania
  • Antonella Tosti, MDAntonella Tosti, MD
    Professor, Department of Dermatology & Cutaneous Surgery, University of Miami, Miami, Florida
Supported by an independent educational
grant from
Valeant Pharmaceuticals
North America LLC
Polling Question

What percentage of your patients who are diagnosed with onychomycosis has diabetes?
Less than 25%
26% to 50%
51% to 75%
Greater than 75%

Disclosures

Steering Committee
Boni E. Elewski, MD

Boni E. Elewski, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Anacor Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Valeant Pharmaceuticals International
Received grants for clinical research from: AbbVie Inc.; Amgen, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Valeant Pharmaceuticals International

Aditya K. Gupta, MD, PhD, FRCPC, FAAD, MBA

Aditya K. Gupta, MD, PhD, FRCPC, FAAD, MBA, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Anacor Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Moberg Pharma; Valeant Pharmaceuticals International
Received grants for clinical research from: Valeant Pharmaceuticals International
Clinical trials investigator: Lilly; Merck & Co., Inc.; UCB Pharma, Inc.

Jeffrey M. Robbins, DPM

Jeffrey M. Robbins, DPM, has disclosed no relevant financial relationships.

Tracey C. Vlahovic, DPM, FFPM RCPS (Glasg)

Tracey C. Vlahovic, DPM, FFPM RCPS (Glasg), has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Pharmaderm; Valeant Pharmaceuticals International

Antonella Tosti, MD

Antonella Tosti, MD has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Anacor Pharmaceuticals, Inc.; PharmaDerm; Polichem; Valeant Pharmaceuticals International; Viamet Pharmaceuticals Holdings, LLC
Served as a speaker or a member of a speakers bureau for: PharmDerm; Sandoz

Dyanne P. Westerberg, DO

Dyanne P. Westerberg, DO, has disclosed no relevant financial relationships.